NCT00431041

Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)

VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 132 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).

Detailed description

This study is a prospective randomized, double-blind, double-dummy, multicentre, 2-arm (1 Active, Active Control) comparative parallel group study to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	solifenacin	Oral
DRUG	oxybutynin immediate release	Oral

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2007-02-02
• Last updated: 2010-06-08
• Results posted: 2010-01-11

Locations

12 sites across 1 country: Canada